63 related articles for article (PubMed ID: 8212641)
21. Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
Pavey SJ; Marsh NA; Ray MJ; Butler D; Dare AJ; Hawson GA
Boll Soc Ital Biol Sper; 1996; 72(11-12):331-40. PubMed ID: 9178585
[TBL] [Abstract][Full Text] [Related]
22. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
23. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
[TBL] [Abstract][Full Text] [Related]
24. Fibrinolytic activity in multiple myeloma.
Yağci M; Sucak GT; Haznedar R
Am J Hematol; 2003 Dec; 74(4):231-7. PubMed ID: 14635202
[TBL] [Abstract][Full Text] [Related]
25. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
[TBL] [Abstract][Full Text] [Related]
26. Enhanced PAI-1 levels from early second trimester and during labour and plasminogen activators in normal pregnancy.
Koh SC; Anandakumar C; Biswas A; Fong YF
Thromb Haemost; 2002 Jan; 87(1):175-6. PubMed ID: 11858184
[No Abstract] [Full Text] [Related]
27. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
[TBL] [Abstract][Full Text] [Related]
28. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
[TBL] [Abstract][Full Text] [Related]
29. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
Agren A; Wiman B; Schulman S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
[TBL] [Abstract][Full Text] [Related]
30. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator.
Deng A; Gocke CD; Hess J; Heyman M; Paltiel M; Gaspari A
Arch Dermatol; 2006 Nov; 142(11):1466-9. PubMed ID: 17116837
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice.
Zhou HM; Bolon I; Nichols A; Wohlwend A; Vassalli JD
Cancer Res; 2001 Feb; 61(3):970-6. PubMed ID: 11221892
[TBL] [Abstract][Full Text] [Related]
32. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
33. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
34. Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome.
Glueck CJ; Sieve L; Zhu B; Wang P
Metabolism; 2006 Mar; 55(3):345-52. PubMed ID: 16483878
[TBL] [Abstract][Full Text] [Related]
35. Hormonal changes in patients with haematological malignancies.
Pavelic K; Pekic B; Gabrilovac J; Bratic-Mikes V; Boranic M
Biomedicine; 1981 Nov; 35(6):181-4. PubMed ID: 6279194
[TBL] [Abstract][Full Text] [Related]
36. [Fibrinolytic system and a central retinal vein thrombosis].
Malukiewicz-Wiśniewska G
Klin Oczna; 1998; 100(3):175-8. PubMed ID: 9814003
[TBL] [Abstract][Full Text] [Related]
37. Serum ferritin levels in hematologic malignant neoplasms.
Patel AR; Shah PC; Vohra RM; Hart WL; Shah JR
Arch Pathol Lab Med; 1980 Oct; 104(10):509-12. PubMed ID: 6932189
[TBL] [Abstract][Full Text] [Related]
38. Forty years later and the role of plasminogen activator inhibitor type 2/SERPINB2 is still an enigma.
Lee JA; Cochran BJ; Lobov S; Ranson M
Semin Thromb Hemost; 2011 Jun; 37(4):395-407. PubMed ID: 21805446
[TBL] [Abstract][Full Text] [Related]
39. Study of foetal antigen in haematological malignancy.
Mukherjee N; Chatterjee D; Biswas TK; Sarkar M
J Assoc Physicians India; 1992 Jun; 40(6):384-7. PubMed ID: 1452563
[TBL] [Abstract][Full Text] [Related]
40. Circulating Fibronectin and Plasminogen Activator Inhibitor-2 Levels as Possible Predictors of Recurrent Placental Syndrome: An Exploratory Study.
Severens-Rijvers CAH; Al-Nasiry S; Ghossein-Doha C; Marzano S; Ten Cate H; Winkens B; Spaanderman MAE; Peeters LLH
Gynecol Obstet Invest; 2017; 82(4):355-360. PubMed ID: 27644043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
